GT BIOPHARMA INC (GTBP) Stock Analyst Earnings Estimates
NASDAQ:GTBP - Nasdaq - US36254L3087 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 61K | 27K -55.74% | N/A -100.00% | N/A | N/A | N/A | 20.474B | 64.804B 216.52% | 97.626B 50.65% | ||||||||||
| EBITDA YoY % growth | -2.374M | -8.925M -275.95% | N/A -5.02% | N/A -1,346.37% | N/A 84.11% | N/A 46.85% | N/A 40.94% | N/A | N/A | N/A | -14.526B | -14.388B 0.95% | -14.753B -2.54% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.396M | -8.927M -272.58% | N/A -5.01% | N/A -1,346.23% | N/A 84.10% | N/A 46.85% | -6.222M 40.96% | -47.086M -750.31% | -21.639M 63.04% | -14.224M 36.13% | -14.526M -7.00% | -14.388M 0.95% | -14.753M -2.54% | -15.133M -2.57% | -15.618M -3.21% | 4.352M 127.86% | 48.359M 1,011.19% | 80.852M 67.19% | |
| Operating Margin | -3,927.87% | -33,062.96% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.02% | 0.07% | 0.08% | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | -6.89 | -51.71 -1,063.40% | -20.04 74.91% | -6.12 71.19% | -6.93 -19.62% | -2.15 68.92% | -1.70 20.85% | -1.83 -7.19% | -1.10 39.66% | -0.26 76.85% | 0.57 324.00% | N/A |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.75 -83.60% | -2.75 -53.00% | -1.58 27.81% | -0.60 63.30% | -0.56 79.63% | -0.52 81.11% | -0.48 69.68% |
| Revenue Q2Q % growth | |||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.292M -18.54% | -4.609M -47.64% | -3.713M -17.20% | -3.75M -21.30% | -3.644M 15.09% | -3.545M 23.10% | -3.451M 7.06% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -1.64 -446.67% | -2.75 | 1.11 | 40.45% |
| Q4 2023 Q2Q % growth | -2.19 59.44% | -2.75 | 0.56 | 20.48% |
| Q3 2023 Q2Q % growth | -1.80 72.73% | -3.06 | 1.26 | 41.18% |
| Q2 2023 Q2Q % growth | -1.50 50.00% | -3.06 | 1.56 | 50.98% |
| Q1 2023 Q2Q % growth | -0.30 94.12% | -4.44 | 4.14 | 93.24% |
| Q4 2022 Q2Q % growth | -5.40 65.38% | -5.36 | -0.04 | -0.84% |
| Q3 2022 Q2Q % growth | -6.60 -15.79% | -3.37 | -3.23 | -96.08% |
| Q2 2022 Q2Q % growth | -3.00 23.08% | -5.36 | 2.36 | 43.98% |
| Q1 2022 Q2Q % growth | -5.10 90.71% | -9.49 | 4.39 | 46.24% |
| Q4 2021 Q2Q % growth | -15.60 84.66% | -6.32 | -9.28 | -146.68% |
| Q3 2021 Q2Q % growth | -5.70 | -6.43 | 0.73 | 11.30% |
| Q2 2021 Q2Q % growth | -3.90 | -8.47 | 4.57 | 53.93% |
| Q1 2021 Q2Q % growth | -54.90 | -7.50 | -47.40 | -632.29% |
| Q4 2020 Q2Q % growth | -101.70 | -1.38 | -100.32 | -7,285.62% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 37.13% |
| Revenue | N/A | N/A | N/A | N/A |